Skip Navigation



Schizophrenia Bulletin Advance Access published online on August 2, 2007
Schizophrenia Bulletin, doi:10.1093/schbul/sbm085
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
33/5/1093    most recent
sbm085v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Stover, E. L.
Right arrow Articles by Marder, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stover, E. L.
Right arrow Articles by Marder, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2007.

New Paradigms for Treatment Development

Ellen L. Stover2, Linda Brady2 and Stephen R. Marder1,3
2 National Institute of Mental Health, Bethesda, MD
3 Semel Institute of Neuroscience at University of California, Los Angeles and the Desert Pacific Mental Illness Research, Education, and Clinical Center, Building 210, Room 130, West Los Angeles Veterans Affairs Healthcare Center, 11301 Wilshire Boulevard, Los Angeles, CA 90073

1 To whom correspondence should be addressed; tel: 310-268-3647; fax: 310-268-4056, e-mail: marder{at}ucla.edu.

Wayne Fenton believed that government—particularly National Institute of Mental Health (NIMH)—could play a critical role in addressing important public health problems where the current system of treatment development was inadequate. Earlier experiences in HIV/AIDS convinced him and others that the NIMH can effectively facilitate the rapid development of new research in critical areas. This report will demonstrate how the work of Fenton and others brought together representatives from industry, government, and academia to address issues that included new preclinical approaches to drug development and defining new therapeutic targets in schizophrenia. An initiative to facilitate the development of new pharmacological agents to address the cognitive impairments in schizophrenia—titled Measurement and Treatment Research to Improve Cognition in Schizophreniaor MATRICS—is used as an example of a new paradigm for treatment development.

Keywords: schizophrenia / treatment / pharmacology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FocusHome page
Bibliography Schizophrenia
Focus, April 1, 2008; 6(2): 197 - 199.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.